Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.16
+0.02 (0.39%)
At close: May 15, 2026, 4:00 PM EDT
5.19
+0.03 (0.58%)
After-hours: May 15, 2026, 7:57 PM EDT
Immuneering Market Cap
Immuneering has a market cap or net worth of $333.84 million as of May 15, 2026. Its market cap has increased by 619.14% in one year.
Market Cap
333.84M
Enterprise Value
138.92M
1-Year Change
619.14%
Ranking
Category
Stock Price
$5.16
Market Cap Chart
Since the IPO on July 30, 2021, Immuneering's market cap has decreased from $365.84M to $333.84M, a decrease of -8.75%. That is a compound annual growth rate of -1.89%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 15, 2026 | 333.84M | -21.43% |
| Dec 31, 2025 | 424.87M | 521.96% |
| Dec 31, 2024 | 68.31M | -68.25% |
| Dec 29, 2023 | 215.13M | 67.99% |
| Dec 30, 2022 | 128.06M | -69.91% |
| Dec 31, 2021 | 425.60M | 16.33% |
| Jul 30, 2021 | 365.84M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Surrozen | 343.11M |
| DiaMedica Therapeutics | 342.70M |
| Atea Pharmaceuticals | 341.72M |
| Silence Therapeutics | 336.78M |
| Nautilus Biotechnology | 332.95M |
| Nuvectis Pharma | 330.24M |
| Invivyd | 328.05M |
| Lineage Cell Therapeutics | 326.58M |